However, the fact that we show that pacritinib blocks glucose consumption in squamous cell lung cancer in vivo without affecting glucose consumption in healthy tissues suggests that a role for FLT3 in driving glucose consumption is cancer specific. The gene discussed is FLT3; the disease is cancer.